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Background: Malignant mesothelioma is a highly aggressive tumor 
arising from mesothelial-lined surfaces, most often in the pleura 
cavities. Antifolates belong to the most effective cytotoxic drugs for 
malignant pleural mesothelioma (MPM) treatment. Pemetrexed is 
an antifolate inhibiting different folate pathway genes (thymidylate 
synthase [TS], dihydrofolate reductase, glycinamide ribonucleo-
tide formyltransferase [GARFT], and aminoimidazole carboxamide 
ribonucleotide formyltransferase, [AICARFT]). Increased activity 
of pemetrexed occurs by folylpolyglutamate synthetase (FPGS), 
intracellular transport by reduced folate carrier (RFC). The aim of 
the study was to explore potential correlations between TS, GARFT, 
AICARFT, RFC, and FPGS levels in MPM and associations with 
clinical benefit from pemetrexed treatment.
Methods: Samples from 63 patients were tested using immunohisto-
chemistry (IHC) and quantitative polymerase chain reaction(qPCR) 
for expression levels of TS, GARFT, AICARFT, RFC, and FPGS. 
Clinical data were evaluated to determine associations between effi-
cacy of pemetrexed and enzyme expression levels. Evaluation of 
expression levels was done through TaqMan-based qPCR, and IHC 
was evaluated semiquantitatively by using the H-score.
Results: qPCR analysis showed no difference in expression pattern 
of GARFT and AICARFT. IHC analysis revealed a heterogeneous 
staining pattern for all the enzymes. No significant association was 
found between TS expression and survival or objective response of 
the tumors after pemetrexed treatment. FPGS (p = 0.0111) and RFC 
(p = 0.0088) mRNA expression levels were strongly associated with 
overall survival in these patients.
Conclusions: Our results reveal that in pemetrexed-treated MPMs 
TS expression levels have no influence on patient outcome. Furthermore, 
GARFT and AICARFT were homogenously expressed in the patient 
samples. Folate uptake mechanisms by RFC and activation by FPGS 
were associated with clinical benefit from pemetrexed treatment.
Key Words: Malignant pleural mesothelioma, Pemetrexed, 
Thymidylate Synthase, Immunohistochemistry, qPCR.
(J Thorac Oncol. 2013;8: 644–653)
Malignant mesothelioma is a highly aggressive tumor arising from mesothelial-lined surfaces like the peri-
toneum and more often, the pleura (malignant pleural meso-
thelioma [MPM]).1,2 Necropsy had revealed metastatic spread 
in 50% of patients3 and untreated, median survival was 9 
months. In the United States, approximately 2500 new cases 
of mesothelioma are diagnosed each year, but the incidence of 
mesothelioma is expected to steadily decline.1,4,5 In contrast, 
the incidence of mesothelioma in Europe, especially Western 
Europe, continues to rise. The peak is expected in the next two 
decades and may account for as many as 250,000 deaths in the 
next 35 years.1,2,6–8 The situation in Australia is similar.1,4
In approximately 80% of MPM patients, a linkage to 
prior asbestos exposure with a latency period of 20 to 30 years 
was found.7,9,10 Although the overwhelming majority of meso-
theliomas is attributed to asbestos exposure, a few other causes 
have been identified.11 MPM is a well-known complication of 
therapeutic radiation for lymphoma, breast cancer, lung can-
cer, or other malignancies. For example, patients with radio-
therapy for Hodgkin’s lymphoma have a 20-fold increased risk 
of developing MPM.11,12
A wide variety of single-agent chemotherapeutics have 
been evaluated for the treatment of MPM.8,13 Cisplatin has been the 
drug of choice for the treatment of mesothelioma, and carboplatin 
seems to have comparable efficacy.1,13–16 The importance of 
platin compounds as a single-agent is declining,1,11,13 with its 
combination with antifolates now considered the most effective 
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regimen for MPM.11,16 Pemetrexed, an antifolate, inhibits 
thymidylate synthase (TS), dihydrofolate reductase, glycinamide 
ribonucleotide formyltransferase (GARFT), and aminoimidazole 
carboxamide ribonucleotide formyltransferase (AICARFT).11,16 
These are the key enzymes for synthesis of essential precursors 
for purine and pyrimidine biosynthesis.
Pemetrexed is the first and only drug that has been 
approved by the Food and Drug Administration for the treat-
ment of mesothelioma.11,16 Several studies have shown the pre-
dicting potential of intratumoral expression of TS mRNA to a 
response to 5-fluorouracil or pemetrexed antifolate therapy in 
patients with thoracic malignancies (non–small-cell lung can-
cer, MPM)17–24 and malignancies of other organ systems,25–28 
but this association was invariably never reported.29,30
The quantification of TS mRNA levels was reported to 
be useful in determining the response in patients with non–
small-cell lung cancer and similarly, the immunohistochemi-
cal evaluation of TS expression to predict survival in untreated 
patients.17,31 An association between high TS expression levels 
and poor prognosis in MPM was also described.32
In the recent literature, a probable correlation between 
TS levels and suboptimal effect of pemetrexed treatment was 
discussed but is not clear in its conclusions.17–35 The possible 
impact of high GARFT and AICARFT levels has not been 
investigated, and another approach to predict the response of 
MPM to pemetrexed, intracellular transport, and activation of 
antifolates should also be considered. In general, three ways 
for the uptake of folic acid and antifolates into the cell are 
known36: the predominant one using the reduced folate carrier 
(RFC), the alternative one using the folate receptor-1, and the 
uptake through the proton-coupled folate transporter.
Folylpolyglutamate synthetase (FPGS) is the cata-
lytic compound for folate activation. This enzyme catalyzes 
the polyglutamylation of antifolates, leading to their activa-
tion.36,37 Pemetrexed, when polyglutamylated, shows a more 
than 60-fold activity in its native form (Fig. 1).38
These aspects have never been taken into account when 
discussing the effector mechanisms of pemetrexed. It is prob-
able that the key for predicting patient responses may lie 
within this area.36,37,39–43
In our study, we aimed to investigate these different 
possibilities of pemetrexed action. Two different methods to 
detect high TS, GARFT, AICARFT, RFC, and FPGS levels 
were used with respect to their feasibility, reliability, and 
application in routine diagnostics.
MATERIALS AND METHODS
Study Design
Patient samples were tested using immunohistochemistry 
(IHC) and by quantitative polymerase chain reaction (qPCR) for 
TS, GARFT, AICARFT, RFC, and FPGS levels. Distribution 
patterns were analyzed and if possible, a cutoff value was 
defined. Afterward, clinical data were evaluated for a clinical 
benefit from pemetrexed treatment and correlated to one or a 
combination of expression levels of the different enzymes.
Patient Samples
Samples from 63 patients with MPM were selected for 
the study. The patients were recruited from the MPM data-
base of the Department of Pathology, Helios Klinikum Emil 
von Behring, Berlin (Germany). Inclusion criteria were the 
availability of sufficient tumor material and administration of 
pemetrexed as a single agent or in combination with platinum 
compounds. For survival analysis, only tumors showing an 
epitheloid histology were included to overcome the problem 
of an inhomogenous data set. Response data were evaluated 
using the the modified Response Evaluation Criteria in Solid 
Tumors for assessment of response in MPM.44 An overview of 
patient data are given in Table 1.
Patient tissue workup postsurgery was performed using 
the standard operating protocol of the Department of Pathology, 
Helios Klinikum Emil von Behring. In brief, after fixation for 
24 hours in 4% buffered formalin, the tissue was embedded in 
paraffin wax and sectioned at 4-µm thickness for slides, used for 
hematoxylin and eosin staining and IHC. In addition, a 20-µm 
thick tissue section was used for molecular analysis. For this 
study, one representative paraffin block from each case was used.
The investigation confirmed the principles outlined in 
the Declaration of Helsinki, and all patient samples were ano-
nymized. An informed consent from all patients was available.
Immunohistochemistry
For further IHC investigations, a tissue microarray 
(TMA) was constructed. After sectioning the blocks for RNA 
extraction, three cores (0.6 mm) were punched from different 
areas of the block. In addition, a core containing benign pleura 
was taken from every sample as a negative control. The three 
tumor-containing cores were extracted to investigate for pos-
sible heterogeneity within the tumor.
IHC staining was done in a standardized way using a 
fully automated processor (Ventana Discovery XT, Tucson, 
AZ). The IHC score was calculated semiquantitatively by 
multiplying staining intensity (0–3) by percentage of stained 
tumor cells (H-score). The mean value of the three cores was 
calculated and used always for further analysis. Mouse primary 
antibodies were used. For a detection system, the ChemMate 
Detection Kit (Dako, Glostrup, Denmark) or the EnVision kit 
(Dako) was used. For visualization, the 3-amino-9-ethylcarba-
zole chromogenic substrate system and the 3,3-diaminoben-
zidine chromogenic substrate system, both Dako, were used.
Stained cores were scored at 200 × magnification by two 
experienced pathologists (HP, ES). On every TMA, benign 
lung tissue was added as a negative control.
Each antibody used was primarily tested on validated 
test tissues. For these tests, a TMA with pulmonary squamous 
cell carcinoma (70 cases of squamous cell carcinomas with 
3 punches for each carcinoma) was used. On these tissues, 
the optimal antibody concentration and pretreatment protocol 
were established and then validated on MPM specimens.
Primary antibodies were purchased from Dako, (Santa 
Cruz, CA), and Abcam (Cambridge, United Kingdom). A list 
containing all antibodies used (including the clones) and their 
exact pretreatment protocols is given in Table 2.
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TABLE 1.  Demographic Data of the Patient Collective, Including Sex, Age, Overall Survival, MPM Histological Subtype, First-
Line Therapy, Chemotherapy Regimens, Response, and Affected Side
No. Sex
Age 
(yrs)
Survival 
(Mo) Histo Surgery Chemotherapy
Response 
(modRECIST) Side
1 M 70 67.43 E Decortication 4 cycles cisplatin/pemetrexed second line SD L
2 M 68 72.1 E Decortication 5 cycles cisplatin/pemetrexed second line SD R
3 M 57 36.43 E Decortication 6 cycles cisplatin/pemetrexed first line SD R
4 M 66 28.9 E Pleuropneumonectomy 6 cycles carboplatin/pemetrexed second line PD L
5 F 77 34.77 E Pleurodesis 3 cycles carboplatin/pemetrexed plus 2 cycles 
pemetrexed monotherapy first line
SD R
6 M 72 21.9 E Decortication 4 cycles carboplatin/pemetrexed first line SD R
7 M 59 8.93 E Pleurodesis 2 cycles carbo/pemetrexed first line PD L
8 M 62 7.27 E Pleurodesis 1 cycle carboplatin/pemetrexed first line NA R
9 M 62 16.6 E Decortication 4 cycles platin/pemetrexed first line NA R
10 M 76 33.93 E Pleurodesis 6 cycles carboplatin/pemetrexed first line SD L
11 M 59 7.27 E Decortication 6 cycles cisplatin/pemetrexed first line SD R
12 M 82 13.5 E Pleurodesis 6 cycles pemetrexed monotherapy first line SD L
13 M 70 48.83 E None 6 cycles platin/pemetrexed first line PR L
14 M 67 20.93 E None 4 cycles carboplatin/pemetrexed first line PD L
15 M 62 35.47 E Decortication 4 cycles cisplatin/pemetrexed first line PR L
16 M 49 16.1 E Pleuropneumonectomy 4 cycles cisplatin/pemetrexed (adjuvant therapy) NA R
17 F 77 81.73 E Decortication 4 cycles carboplatin/pemetrexed first line and 6 
cycles secend line
PR L
18 M 68 53.33 E Decortication 4 cycles cisplatin/pemetrexed first line SD L
19 M 71 15.43 E Pleurodesis 1 cycle carboplatin/pemetrexed first line PD L
20 M 67 16.23 B Decortication 4 cycles carbo/pemetrexed first line PD R
21 M 65 9.67 E Decortication 2 cycles carbo/pemetrexed first line NA R
22 M 67 19.13 E Pleurodesis 6 cycles carbo/pemetrexed first line SD R
23 F 86 27.37 E Pleurodesis 8 cycles pemetrexed mono first line PR L
24 M 69 15.87 E Decortication 3 cycles platin/pemetrexed first line PD L
25 F 63 24.53 E Decortication 6 cycles carbo/pemetrexed first line PR L
26 M 77 62.07 E Decortication 6 cycles platin/pemetrexed first line PR R
27 F 73 48.9 E Decortication 3 cycles cisplatin/emetrexed first line PD L
28 M 69 16.1 E Pleuropneumonectomy 4 cycles cisplatin/pemetrexed (adjuvant therapy) NA R
29 F 64 9.07 E None 2 cycles platin/pemetrexed first line PD R
30 M 67 11.5 S Decortication 6 cycles cisplatin/pemetrexed first line SD R
31 M 73 5.2 E Pleurodesis 3 cycles pemetrexed mono first line NA L
32 M 66 12.33 E Decortication 6 cycles cisplatin/pemetrexed first line SD L
33 M 67 8.53 S Decortication 4 cycles carbo/pemetrexed first line PD L
34 F 69 alive E Pleurodesis 6 cycles cisplatin/pemetrexed first line PR R
35 M 76 22,50 B Decortication 4 cycles carboplatin/pemetrexed first line PR R
36 M 77 28.6 E Decortication 4 cycles cisplatin/pemetrexed first line SD L
37 M 71 18.77 E Decortication 4 cycles cisplatin/pPemetrexed first line SD R
38 M 72 40.37 E Decortication 4 cycles carbo/pemetrexed first line SD R
39 F 54 10.1 E Decortication 5 cycles cisplatin/pemetrexed first line PD R
40 F 64 11.57 B Decortication 4 cycles cisplatin/pemetrexed first line PD R
41 M 81 6.33 B Decortication 3 cycles pemetrexed mono first line PD R
42 M 73 4.67 B Decortication 1 cycle carboplatin/pemetrexed first line NA R
43 M 69 8.13 B Pleurodesis 4 cycles cisplatin/pemetrexed first line PD R
44 M 75 15.37 E Decortication 4 cycles cisplatin/pemetrexed first line PR R
45 M 71 22.73 B Decortication 6 cycles cisplatin/pemetrexed first line PR L
46 M 61 25.63 E Decortication 4 cycles cisplatin/pemetrexed first line SD L
47 M 38 37.03 E Decortication 6 cycles cisplatin/pemetrexed first line PR R
48 M 79 19.27 E Decortication 6 cycles carbo/pemetrexed first line SD L
(Continued )
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Real-Time PCR
RNA was isolated from formalin-fixed, paraffin-embed-
ded (FFPE) tissue. The FFPE blocks were marked by a pathol-
ogist (TM) and indicated tumor. From the blocks three to five 
20-µm thick sections were cut using a slide microtome. Tumor 
tissue was stored at −20°C until used for extraction of RNA. 
For control, benign pleura was processed the same way.
RNA isolation was performed with the RNeasy FFPE 
kit from Qiagen (Venlo, The Netherlands), using adapted 
times and volumes. RNA was stored at −80°C until use.
For cDNA synthesis the iScript Select cDNA Synthesis 
Kit from BioRad (Hercules, CA) was used. cDNA synthesis 
was with 2 µg RNA out of the RNA mix (200 ng/µl), and the 
rest was stored at −80°C for further experiments. The cDNA 
not immediately used was stored at −20°C.
Relative cDNA quantification of TS, GARFT, 
AICARFT, and two housekeeping genes (glyceraldehyde3-
phosphate dehydrogenase [GAPDH] and hypozantine phos-
phoribosyltransferase 1 [HPRT1]), as internal reference 
genes for normalization, were measured in benign tissue 
and tumor specimens. For evaluation, commercial TaqMan 
Gene Expression assays (Applied Biosystems, Foster City, 
CA; AoD, Assay-ID: Hs00269671_m1*, Hs00426586_m1*, 
Hs00894582_m1*, Hs00266705_m1*, and Hs02800695_
m1*, respectively) with optimized primer and probe concen-
trations were used. For the gene expression analysis in FFPE 
tissue, a set of primers with small amplicon size was used 
to overcome the limits of RNA degradation. qPCR and data 
analysis was performed on a Roche LightCycler 480 (Roche 
Applied Sciences, Penzberg, Germany).
Pipetting was augmented by a Hamilton pipetting 
roboter (Reno, NV). Each sample was measured in triplicate. 
Optimal cDNA lots for qPCR analysis were aimed to be in 
the dynamic range, but the use of input material was kept at a 
minimum level. The efficiency of all TaqMan AoD (Applied 
Biosystems) was calculated by their standard curves (see 
below).
Statistical Analysis
For assay validation, standard curves were computed 
using six different concentrations from a pool of all isolated 
RNAs. Calculation was performed automatically with the 
Roche LightCycler 480 program.
To find out the best internal reference gene,45,46 distribu-
tion of the genes in all samples was evaluated with the GenEx 
v5.3.6 (MultiD Analysis, Goeteborg, Sweden) software, using 
the GeNorm and NormFinder algorithm. PCR was analyzed 
by the 2−ΔCt method.45,46
Correlation analysis was performed with a custom-
programmed algorithm for the R software (R Foundation for 
Statistical Computing, Vienna, Austria). The exact Wilcoxon 
Mann–Whitney rank sum test was used to test  associations 
between gene or protein expression and dichotomous vari-
ables (sex). To rule out a possible association between 
gene or protein expression and clinical variables (age, sex, 
TABLE 2.  List of Antibodies Used for Immunohistochemical Detection, Their *Pretreatment Protocols, and the **Detection 
Systems Used
Protein Company, Antibody (Clone) Dilution Pretreatment Detection
AICARFT Santa Cruz, sc-53612 (F38P7H9) 1:1000 MW 9.0 CM DAB
FPGS Abcam, ab 82055 1:50 WB Env+ DAB
GARFT Santa Cruz, sc-100582 1:500 WB ER CM DAB
TS Dako, M3614 (TS106) 1:50 MW 9.0 Env. AEC
RFC Santa Cruz, sc-271276 1:500 MW 9.0 CM DAB
*MW = microwave; WB = waterbath; 9.0,= pH 9.0; **CM DAB= ChemMate DAB Detection Kit, Env + DAB= EnVision kit with DAB+, Env AEC = EnVision AEC kit); AICARFT, 
aminoimidazole carboxamide ribonucleotide formyltransferase; FPGS, folylpolyglutamate synthetase; GARFT, glycinamide ribonucleotide formyltransferase; RFC, reduced folate 
carrier; TS, thymidylate synthase.
49 F 61 12.27 E Decortication 5 cycles cisplatin/pemetrexed first line SD L
50 M 74 29.03 E Decortication 5 cycles carbo/pemetrexed first line SD R
51 F 79 13.77 S Decortication 6 cycles carbo/pemetrexed first line SD L
52 F 64 4.03 E Decortication 3 cycles cisplatin/pemetrexed first line PD R
53 M 67 alive. E Decortication 6 cycles carbo/pemetrexed first line SD L
54 M 71 18.13 E Decortication p6 cycles cisplatin/Pemetrexed first line SD R
55 M 60 13.23 E Decortication 6 cycles cisplatin/pemetrexed first line SD L
56 M 66 12.27 E Decortication 6 cycles cisplatin/pemetrexed first line PD R
F, female; M, male; OS, overall survival; MPM, malignant pleural mesothelioma; Histo, histological subtype; E, epitheloid; B, biphasic, S, sarcomatoid; SD, stable disease; 
PR, partial response; PD, progressive disease; NA, not applicable; R, right; L, left.
TABLE 1. (Continued)
No. Sex
Age 
(yrs)
Survival 
(Mo) Histo Surgery Chemotherapy
Response 
(modRECIST) Side
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etc.) and technical variables (age of the FFPE blocks), a 
Spearman’s rank correlation test was performed. Further, the 
Spearman’s rank correlation test was done to test associa-
tions between gene and protein expression. For correlation 
analysis between the expression status of the different inves-
tigated genes or proteins, we also used the Spearman’s rank 
correlation test.
Overall survival (OS) was calculated by the Kaplan–
Meier method. Analyses of associations between gene or 
protein expression, sex, and age with the OS (from time of 
diagnosis) was done by Cox regression (COXPH model), sta-
tistical significance was determined using likelihood ratio test 
and score (log-rank) test. Level of statistical significance was 
defined as p = 0.05.
RESULTS
Patient Data
From the 63 patients included in this study, there were 
46 men, 12 women and five patients of unknown sex. The 
mean age at date of diagnosis was 66 years, with a median of 
66 years. At date of diagnosis, the oldest patient in the study 
was 84 years of age and the youngest 35 years of age. Survival 
data of 58 patients were available for survival analysis. Fifty-
six of these patients had already died, with only two patients 
still alive at time of data collection. For five patients no fol-
low-up data were available. Median survival was 16.2 months 
(1st Qu.: 11.0; 3rd Qu.: 28.5) with a mean of 22.4 months, 
ranging from 4.0 to 80.6 months.
Quantitative Polymerase Chain Reaction
The assay validation with the standard curves calculated 
an efficiency for GARFT of 1.814, for AICARFT of 1.892, 
and for TS of 2.116. As the optimal amount for future experi-
ments, a final concentration of 10 ng/µl was determined.
The MultiD analysis with GeNorm and NormFinder 
showed an equal distribution of GARFT in all samples, so sub-
sequently, further qPCR results were normalized to GARFT. 
However, AICARFT would also have the potential to be used 
as a housekeeping gene in MPM.
Expression level patterns of GARFT and AICARFT 
were consistently low, thus no difference in expression could be 
detected. Debt to the normalization with GARFT, all 2−ΔCt val-
ues of GARFT became 1. The mean of AICARFT was 0.8517 
with a median of 0.8448. Values of 0.4015 and 1.4175 were 
calculated as a minimum and a maximum value, respectively. 
Standard deviation of all qPCR measurements was below 0.1Ct.
RFC as well as FPGS showed a variable mRNA expres-
sion in all samples. FPGS had a minimum 2−ΔCt value of 
0.0398 and a maximum of 27.4107, RFC had a minimum 2−ΔCt 
value of 0.0810 and a maximum of 40.1780. The mean was set 
at 1.1467 (FPGS) and 1.4224 (RFC), whereas the median was 
0.4699 (FPGS) and 0.3901 (RFC), respectively. One patient 
showed an overexpression of these enzymes, which was not 
correlated to any of the other enzyme expression levels.
TS expression showed small disparities, with cluster 
analysis resulting in two distinct groups. One patient showed a 
significant deregulation. Of the samples analyzed, 27 showed 
a possible up-regulated gene expression, with 19 samples 
showing a normal expression pattern. The mean 2−ΔCt value 
of TS was 2.9554 with a median of 1.7411, whereas the mini-
mum was 0.4166, and the maximum being 40.8803.
Immunohistochemistry
Immunohistochemical staining and validation of all 
five enzymes was successful because all enzymes revealed a 
steady distributed staining pattern. The strongest staining was 
generated with AICARFT, with the lowest IHC values gener-
ated with TS. The gene- and protein-expression data are sum-
marized in Table 3.
Statistical Analysis
Correlation between gene and protein  
expression levels
There was a significant correlation between IHC and 
qPCR results of TS (p = 0.0204), but the association was not 
strong (rho = 0.3526). Surprisingly, gene expression and pro-
tein levels of AICARFT, RFC, and FPGS did not correlate sig-
nificantly with each other (AICARFT, p = 0.2472; RFC, p = 
0.8662; FPGS, p = 0.0671). Between IHC and expression anal-
ysis of GARFT, no correlation analysis could be done because 
of the normalization of the qPCR results with GARFT.
Correlation between gene expression patterns
TS and AICARFT gene expression correlated signifi-
cantly (p = 0.0105) but inversely (rho = −0.3953). None of the 
other combinations rendered statistically significant results 
(TS/RFC, p = 0.2633; TS/FPGS, p = 0.2350; AICARFT/RFC, 
p = 0.0605; AICARFT/FPGS, p = 0.8853; and RFC/FPGS, 
TABLE 3.  Overview of qPCR and IHC Results
Gene Name TS AICARFT GARFT FPGS RFC
Method IHC qPCR IHC qPCR IHC qPCR IHC qPCR IHC qPCR
Min 0.00 0.42 0.00 0.40 0.00 1.00 0.00 0.04 10.00 0.08
Median 5.00 1.74 182.92 0.84 20.00 1.00 39.17 0.47 151.88 0.39
Mean 8.32 2.96 138.60 0.85 39.23 1.00 57.33 1.15 140.94 1.42
Max 63.33 40.88 285.00 1.42 180.00 1.00 186.67 27.41 285.00 40.18
Delta-Ct-values were normalized by AICARFT.
AICARFT, aminoimidazole carboxamide ribonucleotide formyltransferase; FPGS, folylpolyglutamate synthetase; GARFT, glycinamide ribonucleotide formyltransferase; RFC, 
reduced folate carrier; TS, thymidylate synthase; Min, minimum; Max, maximum; IHC, immunohistochemistry; qPCR,quantitaive polymerase chain reaction 
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p = 0.3938). GARFT gene expression levels could not be cor-
related to gene expression levels of TS, AICARFT, RFC, or 
FPGS because GARFT was used for normalization.
Correlation between protein expression patterns
Spearman’s rank correlation test showed a significant 
association between AICARFT and GARFT (p = 0.0023, 
rho = 0.3836) and TS and GARFT protein levels (p = 
0.0005, rho = 0.4304). Correlation analysis between TS and 
AICARFT IHC score did not yield significant results (p = 
0.1717). FPGS and AICARFT (p = 0.0839) and RFC com-
pared with one of the enzymes (RFC/TS, p = 0.6333; RFC/
AICARFT, p = 0.6914; RFC/GARFT, p = 0.3104; and RFC/
FPGS, p = 0.1031) did not show a significant correlation, but 
FPGS and TS and FPGS and GARFT did correlate (FPGS/
TS, p = 0.0294, rho = 0.2791; and FPGS/GARFT, p = 0.0142, 
rho = 0.3126).
Association between gene or protein 
expression levels and sex
TS, GARFT, RFC, and FPGS showed no association 
with sex, protein, or gene expression (TS qPCR, p = 0.4366; 
TS IHC, p = 0.3582; GARFT IHC, p = 0.0970; RFC qPCR, 
p = 0.9688; RFC IHC, p = 0.5451; FPGS qPCR, p = 0.9075; 
FPGS IHC, p = 0.2111). AICARFT gene expression showed 
a significant association with the male sex (p = 0.0253). In 
contrast, protein levels of AICARFT were not associated with 
sex (p = 0.0985).
Correlation between gene or protein 
expression levels and age
No significant correlation between patients’ age and 
expression levels for these enzymes was detected (TS qPCR, 
p = 0.1485; TS IHC, p = 0.5285; GARFT IHC, p = 0.5921; 
AICARFT qPCR, p = 0.6972; AICARFT IHC, p = 0.4292; 
RFC qPCR, p = 0.3147; RFC IHC, p = 0.0517; FPGS qPCR, 
p = 0.3147; FPGS IHC, p = 0.5978).
Correlation between gene or protein 
expression levels and response
No significant correlation between progression of the 
tumor (partial response + stable disease versus progres-
sive disease[PD]) and expression levels for these enzymes 
(TS PCR, p = 0.0891; TS IHC, p = 0.5919; AICARFT 
PCR, p = 0.6520; AICARFT IHC, p = 0.1607; RFC PCR, 
p = 0.1393; RFC IHC, p = 0.5875; FPGS PCR, p = 0.7263; 
FPGS IHC, p = 0.0834) except GARFT IHC (p = 0.0382) 
was detected, and no significant correlation between regres-
sion (partial response versus stable disease+PD) and expres-
sion levels for these enzymes (TS PCR, p = 0.4994; TS IHC, 
p = 0.8067; GARFT IHC, p = 0.2166; AICARFT PCR, p = 
0.6152; AICARFT IHC, p = 0.9670; RFC PCR, p = 0.8143; 
RFC IHC, p = 0.8454; FPGS PCR, p = 0.2525; FPGS IHC, 
p = 0.5343) could be detected either. An overview of correla-
tions between clinical data and expression levels is shown in 
Table 4.
Survival Analysis
Statistical calculation failed to demonstrate an asso-
ciation between age and survival (score [log-rank] test, p = 
0.9476) or sex and survival (score [log-rank] test, p = 0.5550). 
A better distribution in a logarithmic scale of TS qPCR and 
IHC expression was used, and Cox regression analysis was in 
a linear and logarithmic scale.
No significant association was discovered between 
linear or logarithmic scales of TS gene expression and sur-
vival (linear scale: likelihood ratio test = 0.19 on 1 df, p = 
0.6611; logarithmic scale: score [log-rank] test = 0.99 on 1 df, 
p = 0.3187). Neither the linear scale TS IHC (likelihood ratio 
test = 2.42 on 1 df, p = 0.1199) nor the logarithmic scale TS 
TABLE 4.  Overview of Spearman Rank Correlations Test and Exact Wilcoxon Mann–Whitney Rank Sum test p Values Between 
Target Expression and Clinical and Technical Variables
Marker
Clinical Variables Technical Variables
Sex Age Remission Progression Sample Age
p p rho p p p rho
Gene Expression TS 0.4366 0.1485 0.2358 0.4994 0.0891 0.2696 −0.1812
AICARFT 0.0253 0.6972 −0.0662 0.6152 0.6520 0.2969 0.1762
RFC 0.9688 0.3147 −0.1719 0.8143 0.1393 0.1326 0.2553
FPGS 0.9075 0.3147 −0.1675 0.2525 0.7263 0.0279 0.3567
Protein Expression TS 0.3582 0.5285 0.0860 0.8067 0.5919 0.5807 −0.0754
GARFT 0.0970 0.5921 0.0732 0.2166 0.0382 0.2625 −0.1523
AICARFT 0.0985 0.4292 0.1068 0.9670 0.1607 0.0009 −0.4276
RFC 0.5451 0.0517 0.2591 0.8454 0.5875 0.2784 −0.1460
FPGS 0.2111 0.5978 0.0714 0.5343 0.0834 0.4353 -0.1054
A diffuse distribution was observed between all clinical variables and the measured targets; AICARFT seems to be sex-dependent.
AICARFT, aminoimidazole carboxamide ribonucleotide formyltransferase; FPGS, folylpolyglutamate synthetase; GARFT, glycinamide ribonucleotide formyltransferase; RFC, 
reduced folate carrier; TS, thymidylate synthase.
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(Score [log-rank] test = 3.83 on 1 df, p = 0.0804) were associ-
ated with overall survial time.
Statistical analysis of the Cox regression of FPGS and 
RFC showed a strong and significant association between gene 
expression levels of these enzymes (FPGS: likelihood ratio 
test = 6.45 on 1 df, p = 0.011; RFC: likelihood ratio test = 6.86 
on 1 df, p = 0.0088) and OS time.
For visualization of the result of the COXPH analysis, 
Kaplan–Meier curves including a confidence interval of 95% 
were calculated based on existing OS data and are shown in 
Figure 2, with illustrated additional clinical data and com-
bined OS curves.
DISCUSSION
The value of TS expression as a marker for predict-
ing disease response to antifolate therapy remains contro-
versial.17–35 This study was designed to evaluate associations 
between TS expression and clinical benefit by testing OS of 
MPM patients. TS expression level can, therefore, possibly 
serve as a reliable factor for gain of survival in association 
with pemetrexed-based chemotherapy in this tumors, where 
pemetrexed is the standard first-line therapeutic concept. If 
a clear and reliable correlation could be found between TS 
expression and survival or response, it would benefit individu-
alization of MPM therapy, and furthermore, save pemetrexed 
nonresponder patients from inefficient and side effect–loaded 
antifolate therapy. We were aware of the controversies sur-
rounding biomarker for antifolate therapy, thus we investi-
gated the enzymes by using IHC (protein level), and by using 
qPCR for mRNA expression levels. Both levels of expression 
correlated significantly to each other, which is consistent with 
prior studies.21
Our results did not support the hypothesis that low TS 
expression levels in MPM are correlated to clinical benefit 
gained from pemetrexed treatment. However, we were able 
to demonstrate this independently for protein and mRNA 
expression.
Because several other enzymes might act in a similar 
way to TS in nucleotide synthesis, we tested these for their 
relationship to pemetrexed therapy effectiveness. GARFT 
and AICARFT, respectively, were not significantly associated 
with clinical benefit from pemetrexed and were analyzed in a 
monofactorial or multifactorial approach (Table 4).
However, the cellular uptake mechanism by RFC, and 
the activation of antifolates by FPGS, seem to have a strong 
impact on survival time in our collective. Another important 
result for further investigation (shown above) is the perfor-
mance of GARFT as an excellent housekeeping gene in MPM.
Of further interest is the inverse correlation between 
AICARFT protein and gene expression level. It highlights 
the potential presence of regulatory mechanisms on post-
translational level.47 Previous studies also confirm that protein 
expression levels of AICARFT, RFC, and FPGS do not cor-
relate to their gene expression levels.47 Another study result 
of potential importance is the correlation between AICARFT, 
GARFT, and TS protein levels. A significant correlation was 
noted between AICARFT and GARFT, and TS and GARFT 
levels, but the correlation analysis did not render significant 
results between AICARFT and TS. These results suggest that 
GARFT expression plays a role in the regulation of the folic 
acid metabolism.
Nevertheless, cluster analysis generated two distinct 
groups with different TS expression statuses and confirmed 
results from other related studies.16–21,24–28 These clusters, 
unfortunately, were not associated with gain of survival time 
from antifolate therapy in MPM. However, this result is incon-
sistent with published studies,20,21,24 but the possible association 
between TS expression and response to a pemetrexed-based 
chemotherapeutic concept is controversially discussed in the 
recent literature as mentioned above. The differences in these 
studies may be based not only on differences in the collec-
tives, but also on methology for data generation (qPCR, IHC), 
data analysis, and interpretation.
The second approach, besides the effects of members 
of the folic acid cycle, tested in this study was the possible 
impact of enzymes involved in transport and activation mecha-
nisms of folates or antifolates in relation to clinical outcome. 
Surprisingly, this data did render clearly significant results, 
suggesting a strong relevance for these enzymes. In contrast to 
our results, other studies seem to provide data for an association 
of TS and FPGS with progression free survival, but not OS of 
FIGURE 1.  Overview of the cellular folate activation and 
transport mechanisms. After (anti)folate uptake into the cell, 
FPGS adds glutamate groups and leads to an increase of 
activity approximately 60-fold in comparison with the native 
form. FPGS, folylpolyglutamate synthetase; RFC1, reduced 
folate carrier; FR-1, folate receptor 1.
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patients.20 In this study, samples were tested using IHC, which 
could explain the different results.20,48,49 The advantage of IHC 
is the higher level of evidence (mRNA versus translationated 
protein) and the analysis of tumor cells only. Nevertheless, the 
standard IHC has disadvantages in comparison with qPCR 
analysis. IHC in our patients rendered no statistical signifi-
cance, possibly because of the weakness of nonautomated 
evaluation of staining intensities, which results in a high 
inter- and intraobserver variance.50–54 A remedy can be found 
by automated solutions like Automated Quantitative Analysis 
(AQUA) through immunofluorescence measurements,20,55 but 
these newer techniques are in the early stages of development.
A critical review of our results and the recent literature 
directly leads to a paradox situation—this study proves our 
hypothesis that a high TS expression level cannot be the rea-
son for a negative response to multitargeted antifolate therapy. 
In respect to the folate metabolism, there are several required 
mechanisms for the successful synthesis of nucleotides, which 
are involved in several steps for the synthesis of purines and 
pyrimidines (e.g., key-regulatory enzymes such as dihydro-
folate reductase) and even export mechanisms might be rel-
evant. Therefore, the assumption that the blockade of only 
one enzyme (TS) might affect the whole molecular machinery 
does not seem logical. However, our results identified uptake, 
transport, and activation of folates and antifolates as major 
factors responsible for survival.
Despite the negative results toward TS of our study, 
objective response, and disease stabilization after peme-
trexed-based therapy occurs in the majority of patients and 
has been demonstrated in multiple clinical studies. At present, 
pemetrexed therapy is the most promising chemostrategy in 
MPM.
Unfortunately, regardless of the effect of FPGS and 
RFC to gain of overall suvival time, FPGS, RFC, and TS do 
not seem to be associated with the objective response rate to 
pemetrexed-based therapy in our collective (FPGS, p = 0.0834; 
RFC, p = 0.1393; TS, p = 0.5919). Only analysis of GARFT 
protein expression rendered a significant, but weak correlation 
(p = 0.0382). Further studies should take into consideration 
the lack of effect of GARFT levels on OS and the relatively 
steady distribution of GARFT over all samples so that the real 
impact of GARFT expression on response to pemetrexed can 
be conclusively clarified.
Because of the age of the patients’ samples and lack 
of documentation of clinical data, the association between 
expression levels and International Mesothelioma Interest 
Group (IMIG) stages could not be investigated retrospec-
tively. Furthermore, no exact dates of tumor progression could 
be determined and the progression-free survival times could 
not be calculated. Therefore, we focussed on OS and included 
patients with older sample ages in our study from 2002 to 
2009. Only patients collected after 2007 had a standard-
ized first-line chemotherapy with pemetrexed at the Helios 
Klinikum Emil von Behring. All others received pemetrexed 
in second- or third-line therapeutic regimes, sometimes after 
months of PD. It is a widely recognized fact that the response 
rates at second- and third-line chemotherapies differs from 
that of first-line patients.56,57
The question as to what kind of factors strengthen the 
impact found in this study cannot finally be answered here. One 
FIGURE 2.  Kaplan–Meier curve of (A) OS and (B–C) factor-dependent survival (clinical variables,; (D–F) expression of mark-
ers. Censored patients were marked by crosses. Neither age, nor sex, nor the TS expression levels were significantly associated 
with survival. OS, overall survival; CI, confidence interval; TS, thymidylate synthase; FPGS, folylpolyglutamate synthetase; RFC, 
reduced folate carrier.
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possibility could be the differences in pharmacokinetics, as 
total systemic exposure and maximum plasma concentration of 
pemetrexed, increase proportionally with dose.4 In vivo studies 
indicate that approximately 81% of the drug is bound to plasma 
proteins.4 Pemetrexed is excreted renally, the terminal half-life 
in plasma of patients with normal renal function (creatine clear-
ance of 90 ml/min as calculated by the standard Cockroft and 
Gault formula) is 3.5 hours.1,4 After intravenous infusion, 90% 
of the genuine dose is excreted nonmetabolized in the urine 
within 24 hours.1 Total clearance is reduced with decreasing 
renal function, and the use of nonsteroidal anti-inflammatory 
drug (NSAID) may diminish renal clearance of pemetrexed.1,4 
No age effect on the pharmacokinetics was observed on patients 
over the range of 26 to 80 years.4 A pharmacokinetic evaluation 
in patients with third-space accumulation has not yet been done.4
Because our patients were treated at a single-site hospi-
tal we could evaluate this aspect. Thus, we found that the renal 
clearence efficacy of all patients was within normal range, and 
the use of NSAIDs was accurately documented during hos-
pitalization and was not correlated to outcome from peme-
trexed-containing therapy.
In conclusion, it could be demonstrated that the TS 
expression levels and expression levels of other enzymes of 
the folic acid metabolic pathway have no critical influence 
in helping achieve clinical benefit from the antifolate peme-
trexed. Renal clearance and NSAIDs did not separate those 
patients with prolonged or shortened survival time after peme-
trexed-based treatment. However, enzymes of the folic acid 
transport and activating mechanisms (FPGS, RFC) seem to be 
associated with improved survival time. Further studies will 
have to investigate the real catalytic activity of these enzymes 
(functional proteomics) and correlate their mRNA levels to 
objective response rates, and thereby, provide a reliable and 
feasible diagnostic tool for treatment strategies.
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